Please note that following on from information provided to NICE by the company in June 2012, the appraisal of Nesiritide for the treatment of heart failure [ID384] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 384 |
| Referral date | 01 October 2000 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
| 2nd appraisal committee meeting | TBC |
Project Team
| Assessment Group / Evidence Review Group: | Peninsula Technology Assessment Group, University of Exeter |
| Communications manager: | Phil Ranson |
| Executive Lead: | Peter Littlejohns |
| Project manager: | Emily Marschke |
| Technical Lead: | TBC |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 20 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in June 2012, the appraisal of Nesiritide for the treatment of heart failure [ID384] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 10 February 2004 | Date of Information Meeting for Consultees added. |
| 14 January 2005 | Technology Appraisal Project Manager changed. |
| 17 March 2005 | Schedule updated. |
| 6 April 2005 | Date of information meeting for Consultees amended. |
| 27 May 2005 | Provisional schedule updated. |
| 25 August 2006 | This topic was transferred to the Single technology appraisal (STA) process as part of the Institute's 12th wave work programme. |
For further information on our processes and methods, please see our CHTE processes and methods manual